Co-Diagnostics, Inc. - Common Stock (CODX)

Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.

Unusual volume stocks are being observed in Tuesday's session.

Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.

Co-Diagnostics (CODX) stock falls over 50% as they announced a $7 million offering and Saudi joint venture, causing concerns about dilution.

Traders are paying attention to the gapping stocks in Tuesday's session. Let's dive into which stocks are experiencing notable gaps.

The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Stay updated with the latest market activity on Monday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.

Co-Diagnostics shares are trading higher Monday after the company signed a definitive agreement to establish CoMira Diagnostics.

The newly formed joint venture with Arabian Eagle is called CoMira Diagnostics and it will focus on researching, developing, manufacturing, and distributing Co-Diagnostics’ molecular diagnostic technologies.

Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Co-Diagnostics (Nasdaq: CODX) entered a joint venture with Arabian Eagle Manufacturing to develop and commercialize Co-Dx technologies in Saudi Arabia and other Middle East and North Africa countries.

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.